

# INDIRECT COMPARISON OF TREATMENTS IN MODERATE TO SEVERE ATOPIC DERMATITIS

C. MORENO RAMOS, M.D.P. BRICEÑO-CASADO, M.D. GIL-SIERRA,, R. CASTILLEJO-GARCIA,  
SERVICIO EXTREMEÑO DE SALUD, SERVICIOS CENTRALES. SUBDIRECCIÓN DE FARMACIA. MÉRIDA-  
BADAJOZ, SPAIN.

**2SPD-019**  
**D11 OTHER DERMATOLOGICAL**  
**PREPARATION**

## Background and importance

Several systemic treatments are available for moderate to severe atopic dermatitis (AD). Most of these therapies have not been directly compared.

## Aim and objectives

To perform indirect comparisons (ICs) between innovative therapeutic alternatives using a common comparator in patients diagnosed with moderate to severe AD.

## Material and methods


- A PubMed review of pivotal randomized clinical trials (RCTs)
  - Selected therapies: abrocitinib, baricitinib, dupilumab, lebrikizumab, tralokinumab and upadacitinib.
- Inclusion criteria: phase III RCTs, double-blind and placebo-controlled design, patients with moderate to severe AD.
- Investigator's Global Assessment score of 0-1 (IGA 0-1, clear to almost clear skin) at 16 weeks were selected as endpoint to estimate absolute risk reduction (ARR) for each drug.
- The regimen with the greatest magnitude of effect was selected as reference therapy

## Results

Reference therapy: upadacitinib 30mg diary

$\Delta = \pm 23\%$

*Bucher method*



## Conclusion and relevance

- Our ICs provide comparative efficacy data between among therapeutic alternatives for moderate to severe AD in terms of IGA 0-1.
- Statistically significant benefit was observed between upadacitinib 30mg with respect to all treatments, but only relevant clinical superiority over abrocitinib 100mg, baricitinib 2mg and 4mg, lebrikizumab and tralokinumab.

